Roivant Sciences Ltd. (NASDAQ:ROIV) and Priovant Therapeutics have moved quickly to commercialize Lisraya following its FDA approval for dermatomyositis. The partners launched the daily pill immediately and set a list price of $35,000 for a 30-day supply.
The price illustrates the potential value of introducing the first targeted oral treatment for a rare condition with limited options. It also raises the central question facing the launch: whether Roivant and Priovant can secure access and build meaningful adoption within a US population of fewer than 5,000 patients.
Bull Case
Lisraya entered the market immediately after receiving FDA approval, with Priovant CEO Ben Zimmer saying that prescribing is open and that the first patient prescriptions have already been received. While those initial prescriptions do not establish the scale of demand, they show that commercialization began without a lengthy delay following approval. The financial opportunity per patient is substantial, and Roivant CEO Matt Gline estimates that a full year of treatment will produce a net annual value in the low-to-mid $300,000 range per patient. That figure is below the drug’s list price after accounting for expected adjustments, but it still gives Lisraya considerable revenue potential if the partners can reach a meaningful portion of the eligible population.
Roivant also holds the majority economic interest in Priovant, owning 71% of the company. Pfizer, which licensed brepocitinib to Priovant in 2021, owns a 24% stake. Roivant’s controlling position means Lisraya’s commercial performance could become particularly important to its financial outlook. The drug’s clinical evidence also provides support for the launch. In a late-stage trial, patients receiving a daily 30-milligram dose achieved a mean total improvement score of 46.5 after 52 weeks, compared with 31.2 for placebo. The difference was statistically significant, and the companies reported that benefits appeared as early as week four.
Lisraya’s market position could also prove durable. Roivant and Priovant expect the drug to maintain US market exclusivity until at least 2039, potentially giving the partners more than a decade to build prescribing demand without direct generic competition. The companies are also offering a patient-support program that could reduce out-of-pocket costs to zero for eligible patients. That assistance may help some qualifying patients begin treatment despite the high list price.
Bear Case
The $35,000 price for a 30-day supply creates a significant access challenge. A patient-support program may reduce costs for those who qualify, but it could differ in the eligibility requirements, duration, or how many patients could expect to receive assistance. Management is also cautioning investors against expecting immediate commercial scale, with Gline saying that adoption is likely to build gradually. That warning is significant because even a high net value per patient cannot generate substantial revenue unless physicians prescribe the drug and patients obtain access.
The addressable population is exceptionally small. According to the National Institutes of Health, dermatomyositis affects fewer than 5,000 people in the United States, and the number of patients who meet prescribing criteria, receive a diagnosis, and obtain access to Lisraya could be smaller still, although the companies have not provided an eligible-patient estimate.
Conclusion
Positive factors such as Lisraya’s immediate launch, early prescriptions, and long-expected exclusivity give Roivant and Priovant a credible foundation for building a valuable rare-disease franchise. Its clinical results and first-in-category oral formulation strengthen the commercial case.
However, the high price, small patient population, and management’s expectation of gradual adoption make the launch difficult to forecast. Lisraya could generate meaningful value on relatively few patients, but access and sustained prescribing could play a significant role in determining the scale of the opportunity, and not its list price alone.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center